MENLO PARK, Calif. & NAPA, Calif.--(BUSINESS WIRE)--Spinal Modulation, Inc., a privately held global medical device company, today announced the first patient enrollment in its U.S. pivotal clinical trial. The ACCURATE Study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the Axium™ Neurostimulator System for the treatment of chronic lower limb pain. This announcement was made as industry leaders convened last week at the 20th annual Napa Pain Conference, where data were presented about European experience with the Axium System.
Help employers find you! Check out all the jobs and post your resume.
